MOBILE, Ala. / Nov 12, 2024 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that management will participate in the Stephens 2024 Annual Investment Conference to be held November 19-21, 2024, in Nashville, Tennessee.
The fireside chat presentation by Chris Fowler, president and chief executive officer, and Vinay Bassi, chief financial officer, will begin at approximately 2:00 p.m. Central Time on Wednesday, November 20, 2024, and will be available to investors via a live audio webcast. A link to the webcast can be found at the investor relations section of the Company’s website www.trubridge.com.
About TruBridge
We are a trusted partner to more than 1,500 healthcare organizations with a broad range of technology-first solutions that address the unique needs and challenges of diverse communities, promoting equitable access to quality care and fostering positive outcomes. TruBridge has over four decades of experience in connecting providers, patients and communities with innovative data-driven solutions that create real value by supporting both the financial and clinical side of healthcare delivery. Our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings combine unparalleled visibility and transparency to enhance productivity and support the financial health of healthcare organizations across all care settings. We support efficient patient care with electronic health record (EHR) product offerings that successfully integrate data between care settings. Above all, we believe in the power of community and encourage collaboration, connection, and empowerment with our customers. We clear the way for care. For more information, please visit www.trubridge.com.
| Last Trade: | US$22.36 |
| Daily Change: | -0.43 -1.89 |
| Daily Volume: | 105,118 |
| Market Cap: | US$335.620M |
November 06, 2025 October 03, 2025 September 23, 2025 August 07, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load